…
Pediatrix Medical Group, Inc., together with its subsidiaries, provides newborn, maternal-fetal, and other pediatric subspecialty care services in the United States. The company offers clinical care to babies born prematurely or with complications within specific units at hospitals, primarily NICUs, through its network of affiliated neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; and inpatient and office-based clinical care to expectant mothers and unborn babies through its affiliated maternal-fetal medicine subspecialists, obstetricians and other clinicians, maternal-fetal medicine nurse practitioners, certified nurse midwives, sonographers, and genetic counselors. It also provides other pediatric subspecialty care, including pediatric intensivists, pediatric hospitalists, and pediatric surgeons; support services in other areas of hospitals comprising pediatric emergency room, labor and delivery area, and nursery and pediatric departments; a newborn hearing screening program. The company was formerly known as MEDNAX, Inc. and changed its name to Pediatrix Medical Group, Inc. in July 2022. Pediatrix Medical Group, Inc. was founded in 1979 and is based in Sunrise, Florida.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | 216.43M | -101.34M | -48.36M | 81.37M | 135.23M |
| Minority interest | - | 0.00M | 0.00M | 0.00M | 0.03M |
| Net income | 165.39M | -99.07M | -60.41M | 66.33M | 130.96M |
| Selling general administrative | 240.79M | 238.44M | 227.54M | 231.40M | 263.36M |
| Gross profit | 471.88M | 454.34M | 421.56M | 467.03M | 513.24M |
| Reconciled depreciation | 21.83M | 32.23M | 36.17M | 35.64M | 32.15M |
| Ebit | 252.40M | -60.60M | -6.28M | 172.69M | 202.92M |
| Ebitda | 274.22M | -28.37M | 29.89M | 237.36M | 251.80M |
| Depreciation and amortization | 21.83M | 32.23M | 36.17M | 64.67M | 48.88M |
| Non operating income net other | - | - | - | -56.67M | 15.56M |
| Operating income | 231.09M | -68.71M | 7.32M | 172.69M | 202.92M |
| Other operating expenses | 1682.76M | 2081.63M | 1987.32M | 1772.02M | 1693.45M |
| Interest expense | 35.97M | 40.74M | 42.08M | 39.70M | 68.72M |
| Tax provision | 51.04M | -2.27M | 12.05M | 18.81M | 27.24M |
| Interest income | 13.29M | 32.63M | 35.68M | 34.30M | 53.16M |
| Net interest income | -35.97M | -40.74M | -42.08M | -39.70M | -68.72M |
| Extraordinary items | - | 0.00M | 0.00M | 3.77M | 22.95M |
| Non recurring | - | - | - | 27.31M | 22.10M |
| Income tax expense | 51.04M | -2.27M | 12.05M | 18.81M | 27.24M |
| Total revenue | 1913.85M | 2012.92M | 1994.64M | 1972.02M | 1911.19M |
| Total operating expenses | 240.79M | 523.06M | 414.24M | 267.03M | 295.50M |
| Cost of revenue | 1441.97M | 1558.58M | 1573.08M | 1504.99M | 1397.95M |
| Total other income expense net | -14.65M | -32.63M | -55.68M | -91.32M | -67.69M |
| Discontinued operations | - | - | - | 3.77M | 22.95M |
| Net income from continuing ops | 165.39M | -99.07M | -60.41M | 62.56M | 107.99M |
| Net income applicable to common shares | 165.39M | -99.07M | -60.41M | 66.33M | 130.96M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 2246.70M | 2152.70M | 2219.81M | 2347.89M | 2722.55M |
| Intangible assets | 16.86M | 11.60M | 21.24M | 18.49M | 21.57M |
| Other current assets | 21.48M | 18.50M | 25.83M | 28.14M | 51.68M |
| Total liab | 1380.84M | 1387.76M | 1370.75M | 1456.26M | 1825.85M |
| Total stockholder equity | 865.85M | 764.94M | 849.06M | 891.63M | 896.69M |
| Deferred long term liab | - | - | - | 33.64M | 41.41M |
| Other current liab | 382.31M | 316.81M | 279.67M | 199.96M | -22.17M |
| Common stock | 0.83M | 0.86M | 0.84M | 0.83M | 0.86M |
| Capital stock | 0.83M | 0.86M | 0.84M | 0.83M | 0.86M |
| Retained earnings | -83.15M | -248.54M | -149.47M | -89.06M | -155.39M |
| Other liab | - | - | - | 348.68M | 365.91M |
| Good will | 1260.73M | 1242.61M | 1384.17M | 1834.48M | 1794.96M |
| Other assets | 121.33M | 180.45M | 185.02M | 229.10M | 219.37M |
| Cash | 375.24M | 229.94M | 73.26M | 9.82M | 387.39M |
| Cash and equivalents | 375.24M | 229.94M | 73.26M | 9.82M | 387.39M |
| Total current liabilities | 458.91M | 434.11M | 388.95M | 374.23M | 394.12M |
| Current deferred revenue | - | - | -32.43M | 105.92M | - |
| Net debt | 285.06M | 432.37M | 628.39M | 743.74M | 678.44M |
| Short term debt | 38.40M | 33.25M | 35.99M | 36.49M | 22.17M |
| Short long term debt | 25.00M | 18.75M | 12.50M | 14.90M | - |
| Short long term debt total | 660.30M | 662.31M | 701.65M | 753.57M | 1065.83M |
| Other stockholder equity | 947.57M | 1013.69M | 999.91M | 983.60M | 1049.90M |
| Property plant equipment | 73.51M | 78.44M | 145.93M | 73.29M | 70.15M |
| Total current assets | 763.51M | 639.61M | 483.45M | 334.75M | 740.85M |
| Long term investments | - | - | - | 93.24M | 99.72M |
| Net tangible assets | - | - | - | 891.63M | 896.49M |
| Short term investments | 124.48M | 118.57M | 104.48M | 93.24M | 99.72M |
| Net receivables | 242.31M | 272.60M | 279.88M | 296.79M | 301.77M |
| Long term debt | 568.95M | 593.57M | 611.59M | 636.38M | 1002.26M |
| Inventory | - | - | 13.53M | - | - |
| Accounts payable | 37.22M | 46.43M | 34.59M | 31.86M | 394.12M |
| Noncontrolling interest in consolidated entity | - | - | - | - | 0.20M |
| Accumulated other comprehensive income | 0.61M | -1.07M | -2.21M | -3.73M | 1.32M |
| Common stock total equity | - | - | - | 0.83M | 0.86M |
| Retained earnings total equity | - | - | - | -89.06M | -155.39M |
| Non currrent assets other | 37.36M | 76.60M | 82.17M | -105.92M | -88.34M |
| Non current assets total | 1483.18M | 1513.09M | 1736.36M | 2013.14M | 1981.70M |
| Capital lease obligations | 40.66M | 49.99M | 77.56M | 65.80M | 63.57M |
| Long term debt total | 570.53M | 597.12M | 618.42M | 636.38M | 1002.26M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | -3.18M | -35.41M | -46.99M | -56.95M | 1.44M |
| Change to liabilities | - | - | - | -1.35M | -3.48M |
| Total cashflows from investing activities | -18.30M | -35.41M | -48.18M | -56.95M | -53.07M |
| Net borrowings | -20.75M | -15.39M | -19.12M | -401.50M | -759.85M |
| Total cash from financing activities | -107.49M | -14.48M | -25.71M | -487.55M | -760.12M |
| Change to operating activities | - | - | - | 18.73M | 30.32M |
| Net income | 165.39M | -99.07M | -60.41M | 62.57M | 108.01M |
| Change in cash | 145.30M | 156.68M | 63.43M | -377.57M | -736.45M |
| Begin period cash flow | 229.94M | 73.26M | 9.82M | 387.39M | 1123.84M |
| End period cash flow | 375.24M | 229.94M | 73.26M | 9.82M | 387.39M |
| Total cash from operating activities | 271.09M | 206.57M | 137.32M | 166.94M | 76.74M |
| Issuance of capital stock | 3.18M | 3.64M | 5.05M | 5.40M | 6.85M |
| Depreciation | 21.83M | 33.18M | 36.17M | 35.64M | 32.15M |
| Other cashflows from investing activities | -3.46M | 6.83M | 0.81M | -26.79M | 84.87M |
| Dividends paid | - | - | 470.00M | - | - |
| Change to account receivables | 30.56M | 10.29M | 26.28M | -5.54M | -72.73M |
| Sale purchase of stock | -86.68M | -1.70M | -0.92M | -88.51M | -4.72M |
| Other cashflows from financing activities | -3.25M | -1.03M | -10.59M | 1480.73M | 0.41M |
| Change to netincome | - | - | - | 31.38M | -14.16M |
| Capital expenditures | 18.46M | 22.02M | 33.33M | 29.71M | 32.25M |
| Change receivables | - | - | - | -5.54M | -72.73M |
| Cash flows other operating | - | - | - | 38.72M | 52.84M |
| Cash and cash equivalents changes | - | - | - | -377.57M | -736.45M |
| Change in working capital | 41.83M | 88.24M | -11.63M | 31.83M | -23.36M |
| Stock based compensation | 18.05M | 11.87M | 12.32M | 16.13M | 18.97M |
| Other non cash items | -28.18M | 174.49M | 157.63M | 43.55M | -27.80M |
| Free cash flow | 252.63M | 184.55M | 104.00M | 137.23M | 44.49M |
Sector: Healthcare Industry: Medical Care Facilities
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| MD Pediatrix Medical Group, Inc. |
0.28 0.95% |
30.23 | 12.89 | 8.21 | 1.11 | 2.48 | 1.23 | 8.48 |
| HCA HCA Healthcare, Inc. |
15.19 3.30% |
475.52 | 14.27 | 13.46 | 1.21 | 291.34 | 1.83 | 8.99 |
| THC Tenet Healthcare Corporation |
-0.10 0.04% |
263.49 | 10.08 | 12.66 | 0.96 | 4.57 | 1.43 | 5.80 |
| FSNUY Fresenius SE & Co KGaA ADR |
-0.22 1.52% |
14.00 | 16.87 | 9.44 | 0.42 | 0.78 | 0.79 | 5.37 |
| JDHIY JD Health International Inc |
1.31 30.75% |
5.57 | 62.50 | 35.97 | 0.30 | 2.32 | 0.16 | 3.90 |
Pediatrix Medical Group, Inc., together with its subsidiaries, provides newborn, maternal-fetal, and other pediatric subspecialty care services in the United States. The company offers clinical care to babies born prematurely or with complications within specific units at hospitals, primarily NICUs, through its network of affiliated neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; and inpatient and office-based clinical care to expectant mothers and unborn babies through its affiliated maternal-fetal medicine subspecialists, obstetricians and other clinicians, maternal-fetal medicine nurse practitioners, certified nurse midwives, sonographers, and genetic counselors. It also provides other pediatric subspecialty care, including pediatric intensivists, pediatric hospitalists, and pediatric surgeons; support services in other areas of hospitals comprising pediatric emergency room, labor and delivery area, and nursery and pediatric departments; a newborn hearing screening program. The company was formerly known as MEDNAX, Inc. and changed its name to Pediatrix Medical Group, Inc. in July 2022. Pediatrix Medical Group, Inc. was founded in 1979 and is based in Sunrise, Florida.
| Name | Title | Year Born |
|---|---|---|
| Mr. Mark S. Ordan | CEO & Director | 1959 |
| Dr. Roger J. Medel M.D. | Co-Founder & Director | 1947 |
| Mr. C. Marc Richards | Exec. VP & CFO | 1971 |
| Mr. John C. Pepia | Sr. VP & Chief Accounting Officer | 1963 |
| Ms. Mary Ann E. Moore | Exec. VP and Chief Enterprise Risk & Legal Operations Officer | 1960 |
| Dr. James D. Swift M.D. | Exec. VP & Chief Operating Officer | NA |
| Ms. Cheryl M. VanPattan | Sr. VP & Chief Information Officer | NA |
| Mr. Charles W. Lynch C.F.A. | Sr. VP of Fin., Strategy & Investor Relations | NA |
| Ms. Dana Dreher-Rodwell | VP & Chief Compliance Officer | NA |
| Ms. Meghan K. Lublin | Sr. VP, Chief Brand & Communications Officer | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.